Scarica l'app Stockscreener
2.03
0.98%
-0.02
Precedente Chiudi:
$2.05
Aprire:
$2.04
Volume 24 ore:
326.21K
Relative Volume:
0.20
Capitalizzazione di mercato:
$68.29M
Reddito:
$3.04M
Utile/perdita netta:
$-33.97M
Rapporto P/E:
-1.471
EPS:
-1.38
Flusso di cassa netto:
$-52.47M
1 W Prestazione:
-13.62%
1M Prestazione:
-21.01%
6M Prestazione:
-60.51%
1 anno Prestazione:
+0.50%
Intervallo 1D:
$2.01
$2.08
Intervallo di 1 settimana:
$2.00
$2.37
Portata 52W:
$1.90
$8.75
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Nome
Rani Therapeutics Holdings Inc
Settore
Industria
Telefono
(408) 457-3700
Indirizzo
2051 RINGWOOD AVENUE, SAN JOSE
Confronta RANI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| RANI | 2.03 | 68.29M | 3.04M | -33.97M | -52.47M | -1.38 |
| VRTX | 450.15 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.74 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.26 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.93 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.42 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-07-27 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-13 | Iniziato | Wedbush | Outperform |
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
RANI: Third Quarter Update - MSN
HC Wainwright Reiterates "Buy" Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
Rani Therapeutics Advances in Biotherapeutics Market - TipRanks
Rani Therapeutics Holdings Inc (RANI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Rani Therapeutics H - GuruFocus.com
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics Slashes Q3 Loss by 31%, Secures $20M Funding for GLP-1 Development | RANI Stock News - StockTitan
Rani Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) PT at $11.71 - Defense World
Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $11.71 - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Growth in Short Interest - MarketBeat
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch - Simply Wall St
RANI: New Triagonist Data in Weight Loss - Zacks Small Cap Research
Rani Therapeutics shares hold buy rating on positive preclinical data By Investing.com - Investing.com Australia
Rani Therapeutics stock gets positive outlook from H.C. Wainwright after novel obesity candidate progress - Investing.com Australia
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics shares hold buy rating on positive preclinical data - Investing.com
Rani Therapeutics (NASDAQ:RANI) Receives "Buy" Rating from HC Wainwright - MarketBeat
Rani Therapeutics reports promising obesity treatment delivery By Investing.com - Investing.com South Africa
Rani therapeutics sees $10 million in stock sales by major investors By Investing.com - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Sells 3,829,360 Shares - MarketBeat
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics reports promising obesity treatment delivery - Investing.com
Rani Therapeutics Announces New Preclinical Pharmacokinetic - GlobeNewswire
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - The Manila Times
Rani Therapeutics (RANI) Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - StreetInsider.com
Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering - MSN
Recent Insider Activity Could Benefit Comcast Corp (CMCSA) - Knox Daily
Market Momentum: Rani Therapeutics Holdings Inc (RANI) Registers a -33.33 Decrease, Closing at 2.12 - The Dwinnex
There is no doubt that Rani Therapeutics Holdings Inc (RANI) ticks all the boxes. - SETE News
An Analysis of Avidity Biosciences Inc (RNA)’s Potential Price Growth - Knox Daily
Form 424B5 Rani Therapeutics Holdin - StreetInsider.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Why Rani Therapeutics Shares Are Down 23% Today - Benzinga
“Peraso Inc. (NASDAQ: PRSO) Revolutionizes Consumer Experiences with Game-Changing mmWave Technology” more stocks inside…. - The Globe and Mail
Rani Therapeutics Holdings Inc [RANI] is -4.22% lower this YTD. Is it still time to buy? - The DBT News
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 - GlobeNewswire
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants - StockTitan
3 Penny Stocks to Watch Now, 10/15/24 - TipRanks
Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Ubiquiti Inc. (NYSE:UI) Shares Sold by Dimensional Fund Advisors LP - Defense World
Rani Therapeutics Holdings Inc (RANI) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Rani Therapeutics Holdings Inc (NASDAQ:RANI) stock crossing the finish line today - US Post News
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket - Benzinga
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Invests $81,000 in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Buys New Holdings in Hanesbrands Inc. (NYSE:HBI) - Defense World
Investors bid Relief Therapeutics Holding (VTX:RLF) up CHF20m despite increasing losses YoY, taking five-year CAGR to 55% - Yahoo Finance
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics - Yahoo! Voices
Walgreens: A New Risk Just Emerged for the Stock - Yahoo! Voices
Rani Therapeutics Holdings Inc Azioni (RANI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rani Therapeutics Holdings Inc Azioni (RANI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Quiroga Cortes Isidoro Alfonso | 10% Owner |
Nov 24 '23 |
Sale |
2.01 |
5,265,165 |
10,582,982 |
8,400 |
| South Cone Investments Limited | 10% Owner |
Nov 24 '23 |
Buy |
2.01 |
5,265,165 |
10,582,982 |
12,131,554 |
| Imran Talat | Chief Executive Officer |
Dec 06 '23 |
Buy |
2.27 |
10,000 |
22,700 |
484,455 |
| Imran Talat | Chief Executive Officer |
Dec 04 '23 |
Buy |
2.57 |
5,000 |
12,850 |
474,455 |
| Imran Talat | Chief Executive Officer |
Nov 29 '23 |
Buy |
2.05 |
20,000 |
41,000 |
469,455 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):